These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062 [No Abstract] [Full Text] [Related]
3. Irinotecan pharmacogenetics: is it time to intervene? McLeod HL; Watters JW J Clin Oncol; 2004 Apr; 22(8):1356-9. PubMed ID: 15007084 [No Abstract] [Full Text] [Related]
4. Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan. Yau TC; Chu KW; Mok MY; Liang RH; Epstein RJ Acta Oncol; 2005; 44(7):771-2. PubMed ID: 16227172 [No Abstract] [Full Text] [Related]
5. FDA approves irinotecan as first-line therapy for colorectal cancer. Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457 [No Abstract] [Full Text] [Related]
10. Hyoscine and glycopyrrolate for death rattle. Murtagh FE; Thorns A; Oliver DJ Palliat Med; 2002 Sep; 16(5):449-50; author reply 450. PubMed ID: 12380666 [No Abstract] [Full Text] [Related]
11. Scopolamine? Selman D J Am Coll Cardiol; 2002 Feb; 39(4):744-5. PubMed ID: 11849885 [No Abstract] [Full Text] [Related]
12. Audit of three antimuscarinic drugs for managing retained secretions. Hughes A; Wilcock A; Corcoran R; Lucas V; King A Palliat Med; 2000 May; 14(3):221-2. PubMed ID: 10858832 [No Abstract] [Full Text] [Related]
13. Clinical pharmacology and pharmacodynamics of irinotecan. A review. Chabot GG Ann N Y Acad Sci; 1996 Dec; 803():164-72. PubMed ID: 8993509 [No Abstract] [Full Text] [Related]
14. Irinotecan for colorectal cancer: a small step forward. O'Connell MJ Lancet; 1998 Oct; 352(9138):1402. PubMed ID: 9807982 [No Abstract] [Full Text] [Related]
15. New potential uses for transdermal scopolamine (hyoscine). La Rovere MT; De Ferrari GM Drugs; 1995 Nov; 50(5):769-76. PubMed ID: 8586025 [No Abstract] [Full Text] [Related]
16. Irinotecan for metastatic colorectal cancer. Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684 [No Abstract] [Full Text] [Related]
17. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction. Ajani JA Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):17-8. PubMed ID: 11200142 [No Abstract] [Full Text] [Related]
18. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. Mitry E; Ducreux M; Rougier P Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083 [TBL] [Abstract][Full Text] [Related]
19. [Irinotecan hydrochloride for treatment of advanced breast cancers]. Morimoto K; Kou M; Kinoshita H Nihon Rinsho; 2000 Apr; 58 Suppl():265-70. PubMed ID: 11026005 [No Abstract] [Full Text] [Related]
20. Oesophageal spasm, vomiting and hyoscine hydrobromide patch. Murray-Brown F; Davies IL BMJ Support Palliat Care; 2016 Mar; 6(1):125-7. PubMed ID: 26667134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]